View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
December 20, 2019updated 10 Jan 2020 2:47pm

Bayer’s Phase Ib Stivarga with Merck’s Keytruda efficacy/safety data to be revealed at ASCO-GI

The ASCO-GI symposium will take place on 23–25 January 2020 in San Francisco, California.

By GlobalData Healthcare

Bayer ’s 57-patient Phase Ib trial investigating Stivarga (regorafenib) plus Merck’s Keytruda (pembrolizumab) in first-line (1L) hepatocellular carcinoma (HCC) will have efficacy/safety data from the first 30 patients presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) in January, a source familiar with the trial said.

Confirmation of abstract approval was made in the past few days, the source added.

Abstracts for ASCO-GI are scheduled for release mid-December, with the symposium to take place on 23–25 January 2020 in San Francisco, California. A Bayer spokesperson said Phase Ib data will be presented at a future medical meeting. Bayer cannot comment on any potential upcoming ASGO-GI presentations as abstract titles have yet to be published, she added.

Stivarga made $372m in 2018, with Keytruda having sales of $7.1bn. Stivarga is estimated to have $537m in sales in 2025, while Keytruda sales are predicted at $22.1bn in the same year, as per GlobalData consensus forecasts.

Bayer has a $ 71.5bn market cap. shows the open-label Phase Ib trial (NCT03347292) had a study start date of June 2018, with an estimated primary completion date of October 2020. Its primary endpoints are focusing on treatment-emergent adverse events and dose-limiting toxicities, with a follow-up period of 30 days after the last dose and 42 days after the first treatment administration, respectively. The trial has multiple secondary efficacy endpoints like progression-free survival and overall survival with a 36-month time frame.

Phase Ib is divided into two parts. In the dose-escalation part of the trial, patients receive 80mg, 120mg or 160mg oral Stivarga once-daily three weeks on and one week off in combination with 200mg intravenous Keytruda.

This is followed by a dose-expansion portion where cohorts will continue to expand until the sample size of 30–35 patients per cohort is reached, states.

Stivarga is approved for second-line HCC, colorectal cancer and gastrointestinal stromal tumours. Keytruda is used in a variety of cancers including second-line HCC, gastric cancer, oesophageal cancer, among others.

Multikinase inhibitor Stivarga is derived from Bayer ’s Nexavar (sorafenib), which is the current 1L HCC standard-of-care. Nexavar made $840m in 2018, but sales are expected to drop to $64m by 2025, as per GlobalData consensus forecasts. Keytruda is an anti-PD1 monoclonal antibody therapy.

by Reynald Castaneda in London Reynald Castaneda is a Senior Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena